- Home
- EVLV vs CVAC Comparison
EVLV vs CVAC Comparison
Compare EVLV & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVLV
- CVAC
- Stock Information
- Founded
- EVLV 2013
- CVAC 2000
- Country
- EVLV United States
- CVAC Germany
- Employees
- EVLV N/A
- CVAC N/A
- Industry
- EVLV Computer peripheral equipment
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- EVLV Technology
- CVAC Health Care
- Exchange
- EVLV Nasdaq
- CVAC Nasdaq
- Market Cap
- EVLV 1.2B
- CVAC 1.2B
- IPO Year
- EVLV N/A
- CVAC 2020
- Fundamental
- Price
- EVLV $8.20
- CVAC $5.40
- Analyst Decision
- EVLV Strong Buy
- CVAC Hold
- Analyst Count
- EVLV 4
- CVAC 3
- Target Price
- EVLV $8.88
- CVAC $6.83
- AVG Volume (30 Days)
- EVLV 3.8M
- CVAC 501.6K
- Earning Date
- EVLV 08-14-2025
- CVAC 11-11-2025
- Dividend Yield
- EVLV N/A
- CVAC N/A
- EPS Growth
- EVLV N/A
- CVAC N/A
- EPS
- EVLV N/A
- CVAC 1.01
- Revenue
- EVLV $121,011,000.00
- CVAC $599,540,810.00
- Revenue This Year
- EVLV $31.07
- CVAC N/A
- Revenue Next Year
- EVLV $17.67
- CVAC $24.04
- P/E Ratio
- EVLV N/A
- CVAC $5.36
- Revenue Growth
- EVLV 36.64
- CVAC 675.15
- 52 Week Low
- EVLV $2.04
- CVAC $2.37
- 52 Week High
- EVLV $8.91
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- EVLV 59.39
- CVAC 51.65
- Support Level
- EVLV $7.73
- CVAC $5.33
- Resistance Level
- EVLV $8.60
- CVAC $5.41
- Average True Range (ATR)
- EVLV 0.37
- CVAC 0.04
- MACD
- EVLV -0.08
- CVAC -0.00
- Stochastic Oscillator
- EVLV 47.69
- CVAC 61.54
About EVLV Evolv Technologies Holdings Inc.
Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.